Author:
Meadows Jason P.,Mark Tomer M.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology
Reference67 articles.
1. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2009_pops09/ . Accessed May 2013.
2. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565–71.
3. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24(3):431–6.
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
5. FDA Approval for Lenalidomide. Available at http://www.cancer.gov/cancertopics/druginfo/fda-lenalidomide . Accessed May 2013.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献